bendamustine hydrochloride has been researched along with Chemotherapy-Induced Febrile Neutropenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imataki, O; Kadowaki, N; Uchida, S; Uemura, M; Yokokura, S | 1 |
| Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L | 1 |
| Acs, PI; Lee, P; Lynam, E; Rosen, PJ; Tabbara, IA; Vacirca, JL | 1 |
2 trial(s) available for bendamustine hydrochloride and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides | 2018 |
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Incidence; Intention to Treat Analysis; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Patient Dropouts; Rituximab; Secondary Prevention; Survival Analysis; United States | 2014 |
1 other study(ies) available for bendamustine hydrochloride and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Bendamustine and G-CSF support.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy-Induced Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Mantle-Cell; Male; Rituximab | 2019 |